glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Updated evidence on cardiovascular and renal effects of agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Get With the FLOW! in:

Research has demonstrated that simultaneous GIP and GLP-1 receptor stimulation creates a synergistic insulin response and glucagonostatic effect significantly greater than what separate administration of each hormone produces

NICE guidance on chronic primary pain (which includes fibromyalgia) actually advises against starting pregabalin or gabapentin for chronic primary pain

Morning Tea A handful of almonds or a piece of fruit

Clin Interv Aging

Signs of infection at the injection site require medical assessment

Losing weight helps reduce what used to be called non-alcoholic fatty liver disease and is now known as metabolic dysfunction-associated steatotic liver disease or MASLD